Since the 1980s, catheter based therapies such as balloons and stents were introduced and became the dominant technologies over other conventional surgical approaches for the treatment of coronary artery disease. These therapies created a $10 Billion+ market over the next 30 years. The same trend is now starting in Valve Surgery. Interventional Cardiologists in Europe and United States have started to accept the percutaneous replacement of the aortic valve as an alternative to the conventional surgical option among high risk patients with aortic stenosis. Due to its high grade of biological complexity and high surgical risk, mitral regurgitation is considered to be the next big frontier in the device development field.